Name | SCO-267 |
---|
Description | SCO-267 is an allosteric GPR40 full agonist. SCO-267 can be used for the research of chronic diseases including diabetes[1]. |
---|---|
Related Catalog | |
Target |
GPR40[1] |
In Vitro | SCO-267 (CHO cells) activates the Gαq, Gαs, and Gα12/13 pathways and β-Arrestin Recruitment. SCO-267 is allosteric with fasiglifam and an endogenous ligand[1]. |
In Vivo | SCO-267 (1 or 10 mg/kg; p.o.) improves insulin sensitivity and exerts sustained glucose-lowering effect[1]. Animal Model: N-STZ rats[1] Dosage: 1 or 10 mg/kg Administration: P.o.; Result: Improved insulin sensitivity and exerted sustained glucose-lowering effect. |
References |
Molecular Formula | C36H46N4O5 |
---|---|
Molecular Weight | 614.77 |